Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | CDK2 | P24941 | 10/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 10/20 | 0.37 |
| ▸ | CDK5R1 | Q15078 | 10/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 9/20 | 0.37 |
| ▸ | CCNA1 | P78396 | 9/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 8/20 | 0.37 |
| ▸ | CDK1 | P06493 | 2/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | PI4KA | P42356 | 1/20 | 0.31 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.31 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31380754 | 1.00 | ADORA2A (0.45) | ADORA2AADORA1CDK2CDK5CDK5R1 | |
| SCHEMBL31380760 | 0.80 | ADORA2A (0.41) | ADORA2AADORA1CDK2CDK5CDK5R1 | |
| SCHEMBL15922243 | 0.80 | SIGMAR1 (0.36) | — | |
| SCHEMBL17314968 | 0.77 | — | — | |
| SCHEMBL15931260 | 0.77 | — | — | |
| SCHEMBL17314967 | 0.77 | — | — | |
| SCHEMBL20097141 | 0.76 | ADORA2A (0.64) | ADORA2AADORA1CDK2CDK5CDK5R1 | |
| SCHEMBL29661424 | 0.76 | CDK1 (0.41) | ADORA2AADORA1CDK1POLBADORA2B | |
| SCHEMBL183091 | 0.76 | CDK1 (0.41) | ADORA2AADORA1CDK1POLBADORA2B | |
| SCHEMBL24476415 | 0.73 | GAA (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220168309-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE | INVOX PHARMA LIMITED (GB) | 2022-06-02 | — | — | US | disclosed |
| US-20220168309-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE | INVOX PHARMA LIMITED (GB) | 2022-06-02 | — | — | US | disclosed |
| EP-3934652-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE | F-Star Therapeutics, Inc. (GB) | 2022-01-12 | — | — | EP | disclosed |
| CN-113645977-A | Compounds, compositions and methods for treatment of disease | F-星治疗公司 | 2021-11-12 | — | — | CN | disclosed |
| EP-3071570-B1 | 2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | PFIZER (US) | 2018-06-20 | — | — | EP | disclosed |
| CN-105916853-A | 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders | 辉瑞公司 | 2016-08-31 | — | — | CN | disclosed |
| US-9290496-B2 | Purine derivatives | PFIZER INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150141402-A1 | PURINE DERIVATIVES | PFIZER INC. (US) | 2015-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141402-A1 | PURINE DERIVATIVES | ADORA3, ADORA1, HPRT1 | ADORA2A 4/4885ADORA1 2/4885CDK2 279/4885 |
| US-20220168309-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE | STING1, CGAS, MAVS | ADORA2A 436/4885ADORA1 946/4885CDK2 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.